enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment
-
Deadly Russian barrage on Kyiv kills at least 13
-
Campbell back from four years in Wallabies wilderness to face Ireland
-
Next indirect US-Iran talks after Khamenei funeral: mediators
-
Migrants pick up pieces back home after fleeing South Africa
-
Reviving Montenegro's 'ancient' olive tree
-
Farrell names Leinster-heavy Ireland side to face Wallabies
-
Resource rich PNG leaving its Pacific people behind: World Bank
-
Fearing Russian strike, Kyiv's Holodomor museum evacuates exhibits
-
Papal envoy presides over first Vietnam beatification rite
-
Germany's energy-hungry small firms struggle with green shift
-
LeBron James praises Balogun after 'Silencer' celebration
-
Pochettino says Balogun foul 'never' a red card as suspension looms
-
Farrell names Leinster-heavy side to face Wallabies
-
Campbell back after four years in Wallabies team to face Ireland
-
Most Asia markets down as tech firms take fresh blow
-
Kane saves England as USA, Belgium reach last 16
-
South Korean school baseball team suspended over 'Tank Day' chants
-
Budding chefs cook up new career at China's BBQ academy
-
Ceuzany, Cape Verde's golden voice with volcanic emotion
-
One stitch at a time: Artist's mission to recreate the Bayeux Tapestry
-
Balogun scores and sees red as US beat Bosnia 2-0
-
Deadly Russian barrage pounds Ukraine capital
-
EU top court to rule on record 4.1 bn euro Google fine
-
Belgium coach salutes Tielemans after World Cup rescue act
-
'Job forever': trade schools are all the rage in the AI era
-
Cracking open a can of cannabis -- America's new pastime (for now)
-
Celtics reportedly trading Brown to Sixers in NBA blockbuster
-
Russia strikes Ukraine capital with missiles and drones, wounds five
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - July 02
-
Kane saves England after DR Congo scare; Belgium comeback stuns Senegal
-
Belgium late show floors Senegal at World Cup
-
Celtics to trade Jaylen Brown to 76ers for Paul George: report
-
Harry Kane: England's World Cup saviour
-
Streamex is making digital gold accessible
-
US actor Danny Glover says he has Alzheimer's
-
Mixed US auto sales in Q2 amid high gas prices
-
Trump sees progress as US, Iran hold Qatar talks
-
Pistons forward Harris reportedly headed to Spurs
-
Djokovic, Sinner into Wimbledon third round, Andreeva stunned
-
Jovial Djokovic dismantles Tsitsipas to reach Wimbledon third round
-
Spurs agree club record £100 mn move for Newcastle's Tonali - reports
-
US stocks retreat to open Q3 ahead of June jobs data
-
Rain has final say in 1st England-India T20 as Sooryavanshi still awaits debut
-
'Gus' the T. rex presented in New York ahead of auction
-
England refused to accept defeat in 'beautiful' DR Congo win, says Tuchel
-
Kane saves England after DR Congo scare; US eye last 16
-
'Let the dogs in': Sabalenka wants Wimbledon to lift ban
-
Catholic society defies Vatican by consecrating new bishops
-
Oppressive heat broils US during World Cup, July Fourth
-
New York prepares for Taylor Swift-Travis Kelce wedding
enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment
Watch the "What This Means" video here
IRVINE, CA / ACCESS Newswire / September 26, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment.
As part of the segment, Mr. Berman discussed the Company's recent news announcing it filed a request for supervisory appeal of the not-approvable letter from the Center for Devices and Radiological Health (CDRH) of the U.S. Food & Drug Administration (FDA) received on August 19, 2025, in response to its Premarket Approval (PMA) application for the VenoValve®, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).
The Virtual Investor "What This Means" segment featuring enVVeno Medical is now available here.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of severe deep Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The Company is currently performing the final testing necessary to seek IDE approval from the FDA to begin the U.S. pivotal trial for enVVe.
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
[email protected]
(908) 824-0775
MEDIA CONTACT:
Glenn Silver, FINN Partners
[email protected]
(973) 818-8198
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire
T.Perez--AT
